Compare · GTH vs LH
GTH vs LH
Side-by-side comparison of Genetron Holdings Limited (GTH) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GTH and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH is the larger of the two at $25.85B, about 82.4x GTH ($313.7M).
- LH has hit the wire 7 times in the past 4 weeks while GTH has been quiet.
- LH has more recent analyst coverage (25 ratings vs 0 for GTH).
- Company
- Genetron Holdings Limited
- Labcorp Holdings Inc.
- Price
- -
- -
- Market cap
- $313.7M
- $25.85B
- 1M return
- -
- -0.86%
- 1Y return
- -
- +14.64%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 25
Genetron Holdings Limited
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest GTH
- SEC Form 15-12G filed by Genetron Holdings Limited
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form S-8 POS filed by Genetron Holdings Limited
- SEC Form 25-NSE filed by Genetron Holdings Limited
- SEC Form SC 13E3/A filed by Genetron Holdings Limited (Amendment)
- Genetron Health Announces Completion of Going Private Transaction
- SEC Form 6-K filed by Genetron Holdings Limited
Latest LH
- Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
- Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
- Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
- SEC Form DEFA14A filed by Labcorp Holdings Inc.
- SEC Form DEF 14A filed by Labcorp Holdings Inc.
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp Declares Quarterly Dividend
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Announce First Quarter Financial Results on April 30, 2026
- SEC Form 4 filed by Schechter Adam H